Cadina-3,5-diene is a sesquiterpene hydrocarbon found in several conifer, juniper, and manuka-type essential-oil profiles in the AromaForge archive. The strongest public support in this pass is for identity and occurrence data: live chemistry references confirm the molecular formula and archive-linked names, while local oil records place it in juniper whole and manuka oils. Bioactivity evidence is weak and mostly mixture-level, with the best direct literature showing it as one notable component in essential oils that were tested for larvicidal, biting-deterrent, antifungal, or antimicrobial effects rather than as an isolated active.
Chemical identity and composition
PubChem lists cadina-3,5-diene as CID 91723677 with formula C15H24 and the InChIKey JOCWPECWTZZSSX-IHRRRGAJSA-N. NIST indexes the same molecular formula and notes stereoisomer relationships including muurola-3,5-diene forms, which helps explain naming variation across GC-MS reports. Within the archive, juniper whole oil reports cadina-3,5-diene at 3.1% and manuka oil reports it at 5.34%.
Aroma and practical use
- Use the recorded woody, resinous, dry, herbal, resin, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2013 Cupressus arizonica var. glabra study reported cadina-3,5-diene at 6.1% in male-cone oil and 5.8% in needle-twig oil, while the different oils were evaluated for mosquito larvicidal, biting-deterrent, and antifungal effects; only the wood-bark oil showed moderate antifungal activity, so the constituent evidence remains indirect.
A 2013 Cupressus arizonica var. glabra study reported cadina-3,5-diene at 6.1% in male-cone oil and 5.8% in needle-twig oil, while the different oils were evaluated for mosquito larvicidal, biting-deterrent, and antifungal effects; only the wood-bark oil showed moderate antifungal activity, so the constituent evidence remains indirect.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2015 Beilschmiedia glabra essential-oil paper identified cadina-3,5-diene among the characterized components in oils tested for antioxidant, antimicrobial, and anti-inflammatory activity, but the biological results were reported at the oil level rather than for isolated cadina-3,5-diene.
A 2015 Beilschmiedia glabra essential-oil paper identified cadina-3,5-diene among the characterized components in oils tested for antioxidant, antimicrobial, and anti-inflammatory activity, but the biological results were reported at the oil level rather than for isolated cadina-3,5-diene.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific IFRA limit, dermal safety monograph, or human tolerability study was verified for isolated cadina-3,5-diene in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The Good Scents entry shows it as a natural-substances reference with no established fragrance or flavor use recommendation, which is useful as a cautionary data point but not a formal safety assessment.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No isolated constituent pharmacology was verified for cadina-3,5-diene in this pass.
- The published biological signals are mixture-level and do not establish constituent-specific efficacy or mechanism.
- Constituent-specific sensitization, dermal, inhalation, reproductive, and chronic safety data were not verified.
- A c6 verification search (2026-07-13) for cadinene/cadinol RIFM or IFRA data found only a general cadinene assessment (CAS 29350-73-0, a different CAS than this record), so it was not applied here; the prior unsourced 25% dermal_limit_pct and sensitizing:true were corrected to null.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.